8-K: Harmony Biosciences Raises 2025 Revenue Guidance

Harmony Biosciences announced strong preliminary Q3 2025 WAKIX performance, with $239 million in net product revenue and an increased full-year 2025 revenue guidance to $845-$865 million.

Summary

• Harmony Biosciences Holdings, Inc. (HRMY) reported preliminary net product revenue for the third quarter of 2025.
• WAKIX (pitolisant) franchise delivered approximately $239 million in net revenue for Q3 2025.
• This represents a 29% year-over-year revenue growth for the WAKIX franchise.
• The growth was driven by the highest ever quarterly increase in average patients, adding approximately 500 patients to reach 8,100 average patients in Q3 2025.
• The company increased its 2025 revenue guidance to a range of $845-$865 million, up from the previous range of $820-$860 million.
• Full Q3 2025 earnings will be reported, and a conference call will be hosted on November 4, 2025.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to strong preliminary financial results, significant year-over-year revenue growth, record patient additions, and an upward revision of full-year revenue guidance, all indicating robust commercial performance and future growth potential for WAKIX.

Positives

• Preliminary Q3 2025 net product revenue for WAKIX reached approximately $239 million, demonstrating strong performance.
• Achieved 29% year-over-year revenue growth for the WAKIX franchise.
• Recorded the highest ever quarterly increase in average patients for WAKIX, adding approximately 500 patients to reach 8,100.
• Increased the full-year 2025 revenue guidance to $845-$865 million, indicating confidence in continued strong performance.
• The company believes WAKIX is accelerating its trajectory toward potential blockbuster status in narcolepsy.

Risks

• Actual results may differ materially from preliminary results due to quarter-end closing procedures, final adjustments, or other developments.
• Forward-looking statements are predictions, not historical facts, and involve certain risks and uncertainties.
• Actual results, levels of activity, performance, achievements, and events could differ materially from those stated, anticipated, or implied by forward-looking statements.
• Risks discussed under the heading 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, could cause actual results to differ materially.
• The company undertakes no obligation to publicly update or revise any forward-looking statement except as required by law.

Future Outlook

The company is increasing its 2025 revenue guidance, driven by strong WAKIX performance and patient growth, accelerating its trajectory toward potential blockbuster status. Harmony Biosciences plans to explore the therapeutic potential of pitolisant in additional indications and submit an sNDA for pitolisant in idiopathic hypersomnia.

Management Comments

• "Our robust performance this quarter highlights the continued strength of WAKIX and significant market opportunity that remains ahead. I am incredibly proud of our teams focus and executional excellence, as we generated very strong results this quarter, positioning Harmony well for future growth."

Industry Context

Harmony Biosciences operates in the rare neurological diseases sector, focusing on therapies for unmet medical needs. WAKIX, a first-in-class selective histamine 3 (H3) receptor antagonist/inverse agonist, addresses narcolepsy, a chronic debilitating neurological disease affecting approximately 170,000 Americans. The reported strong performance and increased guidance suggest effective market penetration and a significant remaining market opportunity within this specialized therapeutic area.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. However, the 29% year-over-year revenue growth for WAKIX and the highest-ever quarterly patient increase of approximately 500 patients are strong indicators of market acceptance and commercial success within the rare disease pharmaceutical industry, where significant growth rates are often observed for successful orphan drugs.

Stakeholder Impact

• Shareholders are likely to benefit from the strong financial performance and increased revenue guidance, potentially leading to positive stock price movement.
• Patients with narcolepsy continue to have access to WAKIX, with the company's growth indicating continued investment in the product and its market.

Next Steps

• Harmony Biosciences will report full third quarter 2025 financial results on Tuesday, November 4, 2025, before the open of the U.S. financial markets.
• The company will host a conference call and webcast on November 4, 2025, at 8:30 a.m. ET to discuss the results.

Key Dates

Recommendation

The strong preliminary Q3 2025 results, including 29% year-over-year revenue growth for WAKIX and a record increase in average patients, coupled with an upward revision of the full-year 2025 revenue guidance, indicate robust commercial momentum and a positive outlook. These factors suggest that the company is executing effectively and that WAKIX is gaining significant market traction, positioning Harmony Biosciences for continued growth and potentially making it an attractive investment.

Keywords

Harmony Biosciences, HRMY, WAKIX, pitolisant, narcolepsy, revenue guidance, pharmaceutical, rare neurological diseases, Q3 2025 results, biotechnology